Physician profile
Julia Jaffe
NPI 1467880369
$5,893.47
in general payments reported to CMS, 2019-2025
31 companies · $402 in 2025
The $402 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $445 · 2021: $770 · 2022: $1,200 · 2023: $1,158 · 2024: $1,280 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.20 |
| Education | $361.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,466.24 | 2019-2024 | |
| Astellas Pharma US INC | $605.99 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $411.15 | 2019-2022 | |
| Organon LLC | $381.98 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $327.68 | 2022-2025 | |
| Agile Therapeutics, INC. | $306.09 | 2021-2024 | Twirla |
| Evofem Biosciences, INC. | $191.09 | 2021-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $189.18 | 2022-2025 | Slynd |
| Avion Pharmaceuticals | $173.80 | 2020-2022 | |
| Qol Medical, LLC | $172.02 | 2021-2022 | |
| Daiichi Sankyo INC. | $170.19 | 2021-2024 | Injectafer |
| Coopersurgical, INC. | $159.00 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Myovant Sciences INC. | $150.41 | 2021-2022 | |
| Allergan, INC. | $147.30 | 2019-2020 | |
| Aspira Women'S Health INC | $142.46 | 2022-2023 | Ova1 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $129.44 | 2019-2024 | Gardasil 9, Gardasil |
| Scynexis, INC. | $127.62 | 2022 | |
| Sumitomo Pharma America, INC. | $116.25 | 2023-2024 | Myfembree |
| Millicent US INC | $111.59 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Pfizer INC. | $87.75 | 2021-2023 | |
| Hologic Sales and Service, LLC | $69.31 | 2024 | Aptima |
| Lupin INC. | $65.27 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $40.81 | 2020-2024 | |
| Covidien Lp | $32.24 | 2019 | |
| Mimedx Group, INC. | $30.45 | 2024 | |
| Amag Pharmaceuticals, INC. | $21.02 | 2019 | |
| Shield Therapeutics INC | $19.97 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $16.26 | 2022 | |
| Boston Scientific Corporation | $14.61 | 2019 | |
| Dysis Medical, INC. | $13.39 | 2022 | |
| Intuitive Surgical, INC. | $2.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.